Keywords
Efficacy
Obesity
Safety
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the efficacy and safety of GLP-1 analogs as pharmacotherapy for the treatment of obesity based on scientific literature. Methods: This is an integrative literature review, including articles with full text and free access, in Portuguese or English, without a time frame, with searches conducted in the databases Scientific Electronic Library (SCIELO), PubMed, and BVS using health science descriptors in both Portuguese (DeCS) and English (MeSH) combined with boolean operators. The guiding question used was: Are GLP-1 analogs effective and safe for the treatment of obesity? Results: After a thorough selection, 19 articles met the inclusion and exclusion criteria, addressing the guiding question and enriching the review. Final considerations: GLP-1 analogs are safe and effective for the treatment of obesity, showing superior effects compared to other methods, and their efficacy can be enhanced when combined with regular physical activity, a hypocaloric diet, and intensive behavioral therapy. Additionally, they have minimal and tolerable adverse effects with lower risks of complications.
References
ASTRUP A, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP1 analog, liraglutide, Int J Obes (Lond), 2012 Jun; 36(6): 843-54.
BARBOZA JJ, et al. Efficacy of Liraglutide in Non-Diabetic Obese Adults: A Systematic Review and Meta- Analysis of Randomized Controlled Trials, J Clin Med, 2022 May 25; 11(11): 2998.
BROWN EMILY, et al. Newer GLP-1 receptor agonists and obesity- diabetes, Peptides, 2018; 100: 61-67.
DENG Y, et al. Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review, Ther Adv Chronic Dis., 2022 Jul 4; 13: 20406223221108064.
FDA (2021). FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014.
FILIPPATOS, et al. Adverse effects of GLP-1 receptor agonists, The review of diabetic studies: RDS, 2014; 11 (3): 202.
FUJIOKA K. Segurança e tolerabilidade de medicamentos aprovados para controle de peso crônico, Obesidade (Silver Spring), 2015; 23(1): 7-11.
GAO X, et al. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials, Front Pharmacol, 2022 Sep 14;13:935823
GUO X, et al. The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis, Horm Metab Res., 2022 Jul; 54(7): 458-471.
HAINER V. Visão geral de novos medicamentos antiobesidade, Opinião de especialista em farmacoterapia, 2014; 15 (14): 1975–1978.
KNUDSE N, et al. The discovery and development of liraglutide and semaglutide, Frontiers in endocrinology, 2019; 10: 155.
KONWAR M, et al. Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis, Int J Clin Pract, 2022 Jul 19; 2022:1 201977.
LADENHEIM, et al. Liraglutide and obesity: a review of the data so far, Drug design, development and therapy, 2015; 1867-1875.
LE ROUX C, et al. Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis, Obes Facts, 2017; 10(6): 531-544.
LEAN MEJ, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults, International journal of obesity, 2014; 38(5): 689-697
LUNDGREN, et al. Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures, Cardiovascular Diabetology, 2019; 18 (1): 1-9.
MANCINI, M., et al. Tratado de Obesidade, Itapevi: AC Farmacêutica, 2010; 253-264.
MOIZ A, et al. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Am J Cardiol, 2024 Jul 1; 222:121-130.
MONAMI M, et al. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis, Exp Diabetes Res., 2012; 2012: 672658.
OCA, et al. Obesity and GLP-1, Minerva endocrinology, 2021; 46 (2): 168-176.
O'NEIL PATRICK M, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose- ranging, phase 2 trial, The Lancet, 2018; 392 (10148): 637-649.
OMS. Organização Mundial da Saúde. Global Burden Of Disease, 2018.
PI-SUNYER X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management, New England Journal of Medicine, 2015; 373 (1): 11-22.
SMITH I, et al. Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis, Diabetes Metab Syndr Obes., 2022 Dec 17; 15: 3961-3987
TAN HC, et al. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis, J ASEAN Fed Endocr Soc., 2022; 37(2): 65-72.
TRONIERI JS, et al. Effects of dietary self-monitoring, physical activity, liraglutide 3.0 mg, and placebo on weight loss in the SCALE IBT trial, Obesity Facts, 2020; 13(6): 572-583.
WADDEN TA, et al. Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial, Obesity, 2019; 27(1): 75-86.
WILDING JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes Obes Metab, 2022 Aug; 24(8): 1553-1564.
XIE Z, et al. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review, Clin Epidemiol, 2022 Dec 6; 14: 1463-1476.